{"id":59562,"date":"2026-03-16T13:55:12","date_gmt":"2026-03-16T05:55:12","guid":{"rendered":"https:\/\/flcube.com\/?p=59562"},"modified":"2026-03-16T13:55:12","modified_gmt":"2026-03-16T05:55:12","slug":"gsks-arexvy-wins-fda-label-expansion-rsv-vaccine-now-covers-high-risk-adults-aged-18-49","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59562","title":{"rendered":"GSK&#8217;s Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) announced <strong>FDA approval<\/strong> for a <strong>label expansion<\/strong> of its <strong>adjuvanted respiratory syncytial virus (RSV) vaccine Arexvy<\/strong> to include <strong>adults aged 18-49 years at high risk for RSV infection<\/strong>. The approval extends coverage to a <strong>previously unvaccinated population<\/strong> where RSV causes <strong>17,000 annual hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits<\/strong> in the U.S., primarily among individuals with <strong>chronic cardiopulmonary disease, renal disease, obesity, and diabetes<\/strong>. Arexvy is already approved for <strong>high-risk individuals aged 50-59 in 60+ countries<\/strong> and for <strong>adults 18+ in the European Economic Area<\/strong>, with <strong>regulatory decisions pending in China<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Label expansion (new age indication)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Arexvy (RSVPreF3 + AS01E adjuvant)<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>Adults aged 18-49 at high risk for RSV infection<\/td><\/tr><tr><td><strong>Prior U.S. Approval<\/strong><\/td><td>Adults 50-59 at increased risk (underlying medical conditions)<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>\u2022 60+ countries: Approved (50-59 high-risk)<br>\u2022 European Economic Area: Approved (18+)<br>\u2022 China: Regulatory review pending<\/td><\/tr><tr><td><strong>Risk Conditions<\/strong><\/td><td>Chronic cardiopulmonary disease, renal disease, obesity, diabetes<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>16\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-disease-burden-amp-market-opportunity\">Disease Burden &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>U.S. Adults 18-49<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Annual Hospitalizations<\/strong><\/td><td>~17,000<\/td><td>Preventable severe outcomes<\/td><\/tr><tr><td><strong>Emergency Department Visits<\/strong><\/td><td>~277,000<\/td><td>Healthcare cost reduction<\/td><\/tr><tr><td><strong>Outpatient Visits<\/strong><\/td><td>~1.97 million<\/td><td>Productivity preservation<\/td><\/tr><tr><td><strong>High-Risk Population<\/strong><\/td><td>Chronic conditions (cardiopulmonary, renal, obesity, diabetes)<\/td><td>Targeted vaccination strategy<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>No prior RSV vaccines for 18-49 age group<\/td><td>First-to-market advantage<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Age Indication (U.S.)<\/th><th>Mechanism<\/th><th>Arexvy Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Pfizer<\/strong><\/td><td>Abrysvo (RSVpreF)<\/td><td>60+; maternal (infant protection)<\/td><td>Unadjuvanted prefusion F<\/td><td>Adjuvanted (AS01E) enhanced immunogenicity; broader age coverage<\/td><\/tr><tr><td><strong>GSK<\/strong><\/td><td><strong>Arexvy<\/strong><\/td><td><strong>18-49 high-risk; 50-59 high-risk; 60+<\/strong><\/td><td><strong>Prefusion F + AS01E adjuvant<\/strong><\/td><td><strong>First and only RSV vaccine for 18-49 high-risk adults<\/strong><\/td><\/tr><tr><td><strong>Moderna<\/strong><\/td><td>mRESVIA (RSV mRNA)<\/td><td>60+<\/td><td>mRNA<\/td><td>Later market entry; no adjuvant<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-commercial-impact\">Strategic Context &amp; Commercial Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Expansion<\/strong><\/td><td>~15-20 million additional eligible U.S. adults (18-49 with chronic conditions)<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td>Analysts project <strong>$3-4 billion incremental annual sales<\/strong> with 18-49 expansion; total Arexvy franchise approaching <strong>$5 billion peak<\/strong><\/td><\/tr><tr><td><strong>High-Risk Strategy<\/strong><\/td><td>Chronic condition-based indication vs. age-only competitors enables targeted marketing and reimbursement<\/td><\/tr><tr><td><strong>Global Harmonization<\/strong><\/td><td>U.S. label now closer to EU (18+); supports China regulatory submission consistency<\/td><\/tr><tr><td><strong>Combination Potential<\/strong><\/td><td>Future co-formulation with influenza and COVID-19 vaccines in development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regional-regulatory-status\">Regional Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Age Indication<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>18-49 high-risk; 50-59 high-risk; 60+<\/td><td>Approved (March 2026 expansion)<\/td><\/tr><tr><td><strong>European Economic Area<\/strong><\/td><td>18+<\/td><td>Approved<\/td><\/tr><tr><td><strong>60+ Countries<\/strong><\/td><td>50-59 high-risk; 60+<\/td><td>Approved<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>Pending<\/td><td>NMPA review ongoing; decision anticipated 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch performance, China regulatory approval, and competitive positioning for Arexvy in the expanded 18-49 indication. Actual results may differ due to vaccination uptake rates, reimbursement negotiations, and competitive dynamics with Pfizer&#8217;s Abrysvo.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59564,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,184,914,15,12],"class_list":["post-59562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-product-approvals","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK&#039;s Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory syncytial virus (RSV) vaccine Arexvy to include adults aged 18-49 years at high risk for RSV infection. The approval extends coverage to a previously unvaccinated population where RSV causes 17,000 annual hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits in the U.S., primarily among individuals with chronic cardiopulmonary disease, renal disease, obesity, and diabetes. Arexvy is already approved for high-risk individuals aged 50-59 in 60+ countries and for adults 18+ in the European Economic Area, with regulatory decisions pending in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59562\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK&#039;s Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory syncytial virus (RSV) vaccine Arexvy to include adults aged 18-49 years at high risk for RSV infection. The approval extends coverage to a previously unvaccinated population where RSV causes 17,000 annual hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits in the U.S., primarily among individuals with chronic cardiopulmonary disease, renal disease, obesity, and diabetes. Arexvy is already approved for high-risk individuals aged 50-59 in 60+ countries and for adults 18+ in the European Economic Area, with regulatory decisions pending in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59562\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-16T05:55:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK&#8217;s Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49\",\"datePublished\":\"2026-03-16T05:55:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562\"},\"wordCount\":447,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1602.webp\",\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Product approvals\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59562#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59562\",\"name\":\"GSK's Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1602.webp\",\"datePublished\":\"2026-03-16T05:55:12+00:00\",\"description\":\"GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory syncytial virus (RSV) vaccine Arexvy to include adults aged 18-49 years at high risk for RSV infection. The approval extends coverage to a previously unvaccinated population where RSV causes 17,000 annual hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits in the U.S., primarily among individuals with chronic cardiopulmonary disease, renal disease, obesity, and diabetes. Arexvy is already approved for high-risk individuals aged 50-59 in 60+ countries and for adults 18+ in the European Economic Area, with regulatory decisions pending in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59562\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1602.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK's Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59562#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK&#8217;s Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49 - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory syncytial virus (RSV) vaccine Arexvy to include adults aged 18-49 years at high risk for RSV infection. The approval extends coverage to a previously unvaccinated population where RSV causes 17,000 annual hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits in the U.S., primarily among individuals with chronic cardiopulmonary disease, renal disease, obesity, and diabetes. Arexvy is already approved for high-risk individuals aged 50-59 in 60+ countries and for adults 18+ in the European Economic Area, with regulatory decisions pending in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59562","og_locale":"en_US","og_type":"article","og_title":"GSK's Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49","og_description":"GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory syncytial virus (RSV) vaccine Arexvy to include adults aged 18-49 years at high risk for RSV infection. The approval extends coverage to a previously unvaccinated population where RSV causes 17,000 annual hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits in the U.S., primarily among individuals with chronic cardiopulmonary disease, renal disease, obesity, and diabetes. Arexvy is already approved for high-risk individuals aged 50-59 in 60+ countries and for adults 18+ in the European Economic Area, with regulatory decisions pending in China.","og_url":"https:\/\/flcube.com\/?p=59562","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-16T05:55:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59562#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59562"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK&#8217;s Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49","datePublished":"2026-03-16T05:55:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59562"},"wordCount":447,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59562#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1602.webp","keywords":["GlaxoSmithKline","GSK","NYSE: GSK","Product approvals","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59562#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59562","url":"https:\/\/flcube.com\/?p=59562","name":"GSK's Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59562#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59562#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1602.webp","datePublished":"2026-03-16T05:55:12+00:00","description":"GlaxoSmithKline (GSK, NYSE: GSK) announced FDA approval for a label expansion of its adjuvanted respiratory syncytial virus (RSV) vaccine Arexvy to include adults aged 18-49 years at high risk for RSV infection. The approval extends coverage to a previously unvaccinated population where RSV causes 17,000 annual hospitalizations, 277,000 emergency department visits, and 1.97 million outpatient visits in the U.S., primarily among individuals with chronic cardiopulmonary disease, renal disease, obesity, and diabetes. Arexvy is already approved for high-risk individuals aged 50-59 in 60+ countries and for adults 18+ in the European Economic Area, with regulatory decisions pending in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59562#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59562"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59562#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1602.webp","width":1080,"height":608,"caption":"GSK's Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59562#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK&#8217;s Arexvy Wins FDA Label Expansion \u2013 RSV Vaccine Now Covers High-Risk Adults Aged 18-49"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59562"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59562\/revisions"}],"predecessor-version":[{"id":59566,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59562\/revisions\/59566"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59564"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}